Sign in to Peak Brain Path
Sign in to access your courses, books, and progress tracker. New here? Signing in creates your account automatically.
Want to explore courses first?
Browse courses and booksSign in to access your courses, books, and progress tracker. New here? Signing in creates your account automatically.
Want to explore courses first?
Browse courses and booksModule 10
Chapter 10 · 2 h · 8 quiz items · pass at 80%
BCIA Domain V requires the practitioner to know how medication shapes the EEG, because a brain map read without medication history can be read wrong. This module gives the EEG signature of each major drug class and the training-threshold implications, plus the documentation discipline that protects interpretation. The quiz proves the learner can predict a drug's EEG effect and adjust interpretation accordingly.
A client sits down for a brain map. The recording is clean, the artifacting is careful, the database comparison is age-matched, and the report writes itself: elevated frontal theta, a textbook inattentive picture, an obvious protocol. Then the intake form surfaces the detail no one asked about at scheduling. He took his extended-release stimulant four hours ago. Now the map means something different, or rather it means the same numbers under a condition you failed to record, which is a different clinical object. The theta you were about to train may be suppressed by the medication. The beta you noted may be the drug, the caffeine he used to get through the morning, or the muscle tension of a kid who hates electrodes. The map is still real. The interpretation you were about to commit to is no longer safe.
This is the single most common way a competent-looking assessment goes wrong, and avoiding it is a Domain V competency for a reason. Medication and substance exposure change the EEG you record and the thresholds you train against. A practitioner who does not take a medication history before every map, and who does not document it on every recording, is interpreting a moment as if it were a trait. This chapter gives you the drug-class-by-EEG-effect thread you need at the chair: which classes move the signal which way, how that interacts with your training thresholds, when to consider washout, and how to document medication status so the next clinician (or the future you) can read the map correctly. The full pharmaco-EEG framework, the receptor-to-spectrum mechanisms, the confound logic, the worked reports, lives in the companion volume Your Brain on Drugs. This chapter is the practitioner's working subset.
Normative databases are built almost entirely from unmedicated subjects. When you compare a medicated client to an unmedicated norm, you are measuring the mismatch between two states, not the client's stable physiology. A benzodiazepine-driven beta excess flagged against a benzodiazepine-free database reads as "hyperarousal" when it is a pharmacological GABA-A signature. A stimulant-suppressed theta reads as "normal frontal activity" when the unmedicated brain might show the opposite. The database cannot tell you which. Only the medication history can.
The interpretive failure has a name worth knowing: treating a medicated, caffeinated, sleep-variable recording as a clean phenotype. The medication does not invalidate the map. It changes what question the map answers. A recording near a stimulant's peak answers "how does this brain look on medication," which is the right question if the client will train on medication. It does not answer "what is this brain's untreated baseline," and reading it as the latter is the error. Before you record, you have to know what state you are recording so you can say which question the data can address.
The practitioner rule is simple and non-negotiable. Take a full medication and substance history before every brain map: prescription psychotropics, over-the-counter sleep aids, caffeine, nicotine, cannabis, alcohol, and recent changes to any of them. Record the compound, the dose, the last-dose timing, and whether that timing is typical. The most important medication fact is often the one no one thought to ask.
Medication effects do not stop at interpretation. They reach into the live session, because your reward and inhibit thresholds are set relative to the client's current activity, and the medication shapes that activity.
Set a theta-inhibit threshold on a client whose theta is already pharmacologically suppressed by a stimulant, and the threshold may sit so low that the client meets it trivially, learning nothing. Set a beta-reward threshold on a client whose beta is pharmacologically inflated by a benzodiazepine, and you may be rewarding a drug effect rather than a state the client can produce on their own. When a client changes medication mid-course, the baseline the thresholds were calibrated against moves, and a protocol that was working can stop working (or a stalled one can suddenly progress) for reasons that have nothing to do with learning. The threshold is a measurement of the current brain, and the current brain is partly the current pharmacology.
The operating principles follow from that. Set thresholds against the client's actual treated state, the one they will train in, not against an imagined drug-free version. Document the medication state at threshold-setting so a later session can be compared to a like baseline. And when medication changes, re-baseline before you trust the thresholds again, because the comparison across the change is otherwise meaningless.
What follows is the working knowledge for the classes you will see most. The directional effects are reliable enough to guide interpretation; precise magnitudes are not, because the literature reports direction far more consistently than it reports clean numbers. Treat every entry as a confidence adjustment, not a fingerprint.
Methylphenidate and amphetamines increase catecholamine signaling and, in the EEG, tend to reduce excess slow activity and raise faster activity. The primary pediatric anchor found that single-dose methylphenidate reduced frontal and central theta and increased posterior beta in children with ADHD (Clarke et al., 2002), and the broader review literature supports the same direction with heterogeneity across samples (Loo & Barkley, 2005). The non-stimulant attention agents differ and should not be collapsed in: atomoxetine is a norepinephrine reuptake inhibitor with delayed onset and CYP2D6-dependent exposure, recorded as steady-state rather than same-day peak (Clarke et al., 2009).
The training implication is the masking problem. A stimulant can suppress the same frontal theta a theta/beta protocol targets, so a near-peak recording can hide the phenotype you would treat. If the client trains on medication, that treated map is the right one to work from, and you say so. If you need the untreated picture, an off-medication recording requires prescriber coordination and careful control of sleep and caffeine, because a skipped-dose, under-slept, energy-drink morning is not a clean baseline. Adolescent theta/beta ratios warrant extra caution: the ratio shifts with maturation, and a high value in a late teen can reflect development, sleep timing, or cannabis as much as attention physiology.
Benzodiazepines are positive allosteric modulators at GABA-A receptors, and they produce the most counterintuitive signature in this chapter. They increase beta activity while sedating the client (Mandema et al., 1992). The map looks fast while the person is slowed. Beta excess under benzodiazepine exposure does not mean what beta excess means in an unmedicated anxious client, and treating the two as interchangeable is the most common error in medicated-QEEG beta interpretation. Spindling beta in the 15 to 18 Hz range is a recognized qualitative signature of this class.
For thresholds, the hazard is obvious: a beta-reward protocol can end up rewarding drug-driven beta, and a high-beta-inhibit protocol can chase a pharmacological feature the client cannot lower by learning. Document the exposure and the timing precisely. "Recorded two hours after PRN alprazolam" tells you far more than "takes alprazolam as needed." Discontinuation is its own state and a safety matter: benzodiazepine withdrawal can produce beta rebound, hyperexcitability, and seizure risk, and an abrupt taper is a reason to defer confident phenotyping, not a clean off-medication baseline. Never frame a withdrawal recording as "off benzodiazepines."
Antidepressants are among the most common exposures you will see, and they resist a single EEG signature. Effects vary by compound, dose, responder status, sex, and the recording method, and the directions reported across studies are inconsistent (Saletu, Grunberger & Linzmayer, 1986). The practitioner-relevant caution is about frontal alpha asymmetry, the antidepressant marker most likely to be overread: its predictive value is sex-dependent and method-sensitive, and a recent meta-analysis found a near-zero pooled effect for resting FAA in depression, so it should never be presented as a universal SSRI response biomarker (Allen & Cohen, 2010). Alpha and individual alpha frequency also shift with reproductive-hormone state, so a low-alpha finding in a woman on an SSRI carries menstrual-cycle, contraceptive, and perimenopausal context that has to be weighed before the medication gets the credit.
For interpretation and thresholds, the useful posture is conditional. Activation effects (insomnia, agitation, restlessness) can push arousal and beta. Sedating effects can do the opposite. Discontinuation produces its own state that is not a never-medicated baseline. Document the compound, dose, duration, recent changes, and any reported activation or sedation, and adjust confidence in arousal-based findings accordingly rather than assigning them to a stable trait.
Typical (first-generation) antipsychotics are dopamine D2 antagonists that shift the EEG toward slowing: increased delta and theta, alpha slowing and profile change, sometimes reduced fast activity (Itil et al., 1987). The direction is dependable; precise magnitudes are not, and you should not attach a specific hertz value to the alpha shift, because the topographic literature does not support a clean number (Saletu et al., 2002). This slowing can mimic underarousal, frontal theta, or a medication-burden picture, which matters because these clients often also carry anticholinergic adjuncts, benzodiazepines, nicotine, and disrupted sleep, all pushing the same direction.
Atypicals (second-generation) are more varied. Risperidone increased absolute delta and theta across leads after a single dose in healthy volunteers (Lee et al., 1999). Clozapine carries strong EEG effects and seizure-threshold concerns, and its exposure is sensitive to smoking: clozapine is a CYP1A2 substrate, so quitting smoking can raise plasma levels and increase slowing on an unchanged dose, which means smoking status belongs in the record at every recording. Olanzapine slows less than clozapine in comparative work but is not EEG-neutral. Aripiprazole does not fit the sedating-slowing model and can produce activation or akathisia, so a beta-heavy or movement-contaminated recording under aripiprazole should not be read automatically as anxiety. The threshold implication across the class: slowing can drag a theta-inhibit threshold into a range where the client trivially succeeds, and you re-baseline when the regimen changes.
This class is heterogeneous by mechanism and demands compound specificity. A global "mood stabilizer" label is too vague to interpret. Lithium produces qualitative slowing and reduced alpha organization, not the beta increase sometimes loosely attributed to it, and a slowed map in a lithium-treated client should be read alongside serum level, hydration, and toxicity context (Reischies & Neu, 2000). Lamotrigine runs the opposite way from the common misconception: it reduces delta and theta power while preserving alpha mean frequency, making it relatively EEG-sparing rather than alpha-elevating, so do not write that lamotrigine raises alpha (Clemens et al., 2007). Topiramate is associated with slowing and the cognitive-slowing complaints clients report on it (Cai, Chen & Wu, 2003). Gabapentin and pregabalin reach the EEG mainly through drowsiness and the conditions they treat (pain, sleep, anxiety) rather than a clean spectral fingerprint, and the broader antiepileptic literature supports class-level orientation without blurring compound differences (Perucca & Perucca, 2016). Because several of these reduce slow activity or stabilize the record, a normal-looking map under them does not certify a normal untreated baseline; it may show treated stabilization, and missed-dose or taper states should be labeled as transitions, not baselines.
Opioids act primarily at the mu receptor and tend toward slowing and altered arousal. The clearest evidence is in methadone maintenance, where resting EEG shows qualitative theta and beta differences versus controls (Liang et al., 2015). Evidence for many other opioid contexts (acute postoperative use, buprenorphine maintenance, fentanyl patches, tramadol) is sparse, so generalize cautiously and lean on practice-level synthesis where direct data are absent (Kerson, 2023). The interpretive trap is composite: in chronic pain, the slowing you see may be the opioid, the pain itself, poor sleep, a gabapentinoid, or an obstructive-sleep-apnea load, and the map is rarely one clean cause. Withdrawal flips the direction toward hyperarousal, insomnia, and beta or artifact elevation, and is a transformation state rather than an off-medication baseline. Maintenance on a stable dose is best read as the treated state in which training will occur.
Cannabis resists a single signature, and the most important correction is that chronic use does not produce one consistent alpha direction. The heterogeneous picture across cohorts includes reduced delta and theta with elevated beta and gamma in some chronic-use samples (Prashad, Dedrick & Filbey, 2018) and regionally dissociated alpha findings, with frontal and posterior patterns diverging, in long-term users during abstinence (Struve et al., 2008). Acute intoxication is a state recording, not a phenotype map. Product, route, potency, and last use all matter, and a single intake checkbox for "marijuana" does not capture the difference between a high-THC concentrate, a balanced edible, and wellness-dose CBD (which has little reliable resting-EEG signature and is not the same exposure as THC). Adolescent cannabis use intersects with developmental maturation and should not be read through adult frameworks. For thresholds, the heterogeneity itself is the caution: a fast-activity finding under chronic cannabis may not mean ordinary anxiety, and abstinence duration shapes what you are seeing.
Alcohol is common, underreported, and strongly state-dependent, and the separation between acute, withdrawal, chronic-use, and abstinent states is the whole interpretive game. Acute low-to-moderate alcohol tends to increase alpha (Lukas et al., 1986). The chronic and familial-risk literature points the other way at the trait level, supporting elevated beta as a persistent signature in alcohol-use disorder and family-risk populations (Rangaswamy et al., 2002; Ehlers et al., 1991). The practitioner-critical point is the pristine-baseline problem: a recording during abstinence after heavy use is not a never-exposed baseline, because elevated beta and other signatures can persist for months to years (Bauer, 2000). Elevated beta in a client with an alcohol history reads differently from beta in a caffeine-anxious client, and alcohol history belongs in the differential before you label that beta as anxiety, trauma hyperarousal, or artifact. Withdrawal is a safety matter (seizure and kindling risk) and a medical-care priority, not a phenotype. Ask about drinking directly and without judgment, because shame produces inaccurate histories, and an inaccurate alcohol history weakens every interpretation downstream.
Whether to record on or off a substance is a clinical decision tied to the question you are asking, and it is constrained by safety.
For acute exogenous substances the practitioner can reasonably ask the client to hold, caffeine, nicotine, cannabis, and alcohol, standard pre-recording cutoffs apply, and the cleaner the hold, the cleaner the baseline, provided the hold does not itself create a withdrawal state. For prescribed psychotropics taken daily, the usual approach is to record before that day's morning dose, capturing a defined trough without a medication skip, then have the client dose immediately after. A true off-medication washout is a different and heavier decision. For stimulants, an extended hold is sometimes used to evaluate the unmedicated phenotype, and because that is a timing hold rather than a discontinuation, it requires prescriber coordination and control of sleep and caffeine to be meaningful. For benzodiazepines, antipsychotics, anticonvulsants, and antidepressants, you do not direct an off-medication recording on your own initiative: discontinuation of these classes carries medical and psychiatric risk and belongs to the prescriber. The boundary is firm. A neurofeedback practitioner does not start, stop, or change medication, and does not ask a client to do so unsupervised, no matter how much cleaner the map would be.
When the goal is specifically the medicated phenotype, a treated-state recording is correct and you label it as such. When the goal is comparison, two recordings (usual-state and a carefully documented alternative state) tell you more than one, with the understanding that the comparison is descriptive and does not by itself prove the medication caused every difference.
The medication note is a load-bearing part of the clinical record, not a formality, because the next person to read the map (a colleague, a re-assessing clinician, or you in six months) cannot reconstruct the recording state from the numbers alone.
For every brain map and every threshold-setting session, the record should capture: each medication and substance, with compound, dose, and formulation; last-dose timing and whether it is typical; recent regimen changes (new starts, dose adjustments, tapers, missed doses); caffeine, nicotine, cannabis, and alcohol in the relevant window; and sleep the night before. The report language should name the state explicitly. "Recorded near expected peak of extended-release stimulant; frontal theta was not elevated under this treated condition, so the unmedicated theta phenotype cannot be determined from this recording alone" is defensible. "Stimulants normalized the QEEG" is not. The phrasing that protects you and serves the client is conditional and state-specific: name the exposure, name what it does to confidence, and stop short of causal claims the recording cannot support.
A training course is rarely pharmacologically static. Clients start medications, adjust doses, taper, skip, and add over-the-counter sleep aids, and each change moves the EEG you are training and the thresholds you set.
Watch for the change and treat it as a re-assessment trigger. A new stimulant or dose increase can suppress theta and shift the thresholds your theta/beta protocol depends on. A new benzodiazepine or sleep aid can inflate beta. An antidepressant taper can produce a discontinuation state that looks like worsening when it is transitional. When a client reports a medication change, re-baseline before trusting the existing thresholds, document the change in the session record, and read subsequent progress against the new baseline rather than the old one. A protocol that stalls or surges right after a regimen change is telling you about the pharmacology, not necessarily about the learning, and Chapter 13's failure-checkpoint logic should always rule out a medication change before you blame the protocol.
Medication status belongs in the consent conversation because it bears on what your assessment can and cannot claim. When you explain the brain map to a client, the honest version includes the caveat that the map reflects their current medicated and rested state, that it cannot by itself reveal their untreated physiology, and that it does not diagnose a condition or direct their medication. That last point is a scope boundary you state plainly: the QEEG informs the conversation between client and prescriber, and it does not replace it. A client who reads "masked ADHD phenotype" on a report may ask about stopping a medication, and the report's language has to be disciplined enough not to invite that. Coordinate any medication question with the prescriber, document that you did, and keep your own claims inside what a medicated recording can support.
Strip this chapter to what you do when a client sits down for a map. You take a full medication and substance history first, every time, including caffeine, nicotine, cannabis, and alcohol, with compound, dose, and last-dose timing. You decide before the appointment what state to record and which question the map will answer, holding acute substances where you safely can and recording prescribed psychotropics at trough, never directing an unsupervised washout of a class that is dangerous to stop. You set thresholds against the treated state the client will train in, document that state, and re-baseline when the regimen changes. You write the medication note as a load-bearing record and keep your interpretation conditional. And you forward-reference Your Brain on Drugs when a regimen raises a question this chapter does not answer, because the full pharmaco-EEG framework lives there.
For the BCN exam, hold the directions and the traps. Stimulants reduce theta and raise beta, and a near-peak recording masks the attention phenotype. Benzodiazepines augment beta while sedating, so benzodiazepine beta is not anxiety beta. Typical antipsychotics and many opioids slow the record; lithium and topiramate slow it too, while lamotrigine reduces slow activity rather than raising alpha. SSRIs are variable, and frontal alpha asymmetry is not a universal antidepressant biomarker. Cannabis is heterogeneous, not uniformly alpha-elevating. Alcohol increases alpha acutely and leaves a persistent beta signature in alcohol-use disorder, so abstinence is not a never-exposed baseline. Normative databases assume an unmedicated subject, which is why the medication history is mandatory before every map, and why the recording state must be documented on every record you sign.